Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study F. Valenzuela, C. de la Cruz Fernandez, R.L. Galimberti, S. Gürbüz, M. McKean-Matthews, L. Goncalves, R. Romiti

Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice S. Berenguer-Ruiz, M. Romero-Dávila, M. Aparicio-Domínguez, M. Olivares-Guerrero, E. Daudén, M. Llamas-Velasco

Pathogenic role of IL-17 in psoriasis and psoriatic arthritis A. Chiricozzi